CUMBERLAND PHARMACEUTICALS INC (CPIX)
↓ Download CSV- Sector Manufacturing
- Incorporated TN
- Fiscal year ends Dec 31
In fiscal 2025, CUMBERLAND PHARMACEUTICALS INC reported revenue of $44.52M, up 17.6% from the prior year. The company ran a net loss, with a net margin of -6.4%. It held $76.82M in total assets against $52.28M in total liabilities.
Key ratios (FY2025)
-6.3%
Operating margin
-6.4%
Net margin
-11.6%
Return on equity
+17.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.52M | $37.87M | $39.55M | $42.01M | $35.05M | $35.84M | $32.41M | $28.80M | $40.38M | $32.48M |
| Cost of Revenue | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M | $7.42M | $6.02M | $7.37M | $5.96M |
| Operating Income | -$2.79M | -$6.43M | -$9.55M | -$5.70M | -$7.68M | -$6.38M | -$9.29M | -$11.17M | -$4.08M | -$1.43M |
| Net Income | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M | -$3.34M | -$3.54M | -$6.96M | -$7.98M | -$944.7K |
| EPS (Diluted) | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
| Total Assets | $76.82M | $75.58M | $81.78M | $92.93M | $84.46M | $96.46M | $104.55M | $112.69M | $93.23M | $93.40M |
| Total Liabilities | $52.28M | $53.04M | $52.52M | $56.95M | $41.86M | $49.59M | $53.46M | $57.12M | $29.31M | $20.28M |
| Shareholders' Equity | $24.54M | $22.55M | $29.26M | $35.97M | $42.60M | $46.87M | $51.09M | $55.57M | $63.92M | $73.12M |
| Cash & Equivalents | $11.44M | $17.96M | $18.32M | $19.76M | $27.04M | $24.75M | $28.21M | $27.94M | $45.41M | $34.51M |
| Operating Cash Flow | $4.93M | -$612.2K | $6.09M | $8.45M | $6.34M | $5.42M | $3.06M | $3.11M | -$557.7K | $569.5K |
| Capital Expenditures | $97.9K | $66.5K | $281.3K | $102.1K | $103.5K | $140.8K | $246.2K | $455.6K | $276.0K | $130.9K |
| Shares Outstanding | 14.85M | 14.06M | 14.30M | 14.56M | 14.90M | 15.16M | 15.40M | 15.61M | 15.91M | 16.24M |